

Henrik Roed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12093115/publications.pdf>

Version: 2024-02-01

32
papers

1,649
citations

430754

18
h-index

454834

30
g-index

32
all docs

32
docs citations

32
times ranked

1825
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 791-798.	1.1	17
2	Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2019, 155, 530-537.	0.6	22
3	Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. <i>Lancet Oncology</i> , The, 2019, 20, 1409-1419.	5.1	179
4	Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 93-98.	0.9	2
5	Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free studyâ€”NSGO-AVANOVA2/ENGOT-OV24.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5505-5505.	0.8	10
6	¹⁸ Fâ€”FDG PET/CT for planning external beam radiotherapy alters therapy in 11% of 581 patients. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 278-284.	0.5	6
7	Cervical cancer staging, pretreatment planning, and surgical treatment in the Nordic countriesâ€”Survey from the Surgical Subcommittee of the Nordic Society of Gynecological Oncology. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 1178-1184.	1.3	3
8	Visual outcome, endocrine function and tumor control after fractionated stereotactic radiation therapy of craniopharyngiomas in adults: findings in a prospective cohort. <i>Acta OncolÃ³gica</i> , 2017, 56, 415-421.	0.8	22
9	Preliminary phase II results of selinexor, an oral selective inhibitor of nuclear export in patients with heavily pretreated gynecological cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5565-5565.	0.8	4
10	Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors. <i>Journal of Neuro-Oncology</i> , 2014, 118, 101-108.	1.4	26
11	In Reply to Maletz etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1153-1154.	0.4	0
12	Fractionated Stereotactic Radiotherapy of Vestibular Schwannomas Accelerates Hearing Loss. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e607-e611.	0.4	41
13	The diagnostic value of PET/CT scanning in patients with cervical cancer: A prospective study. <i>Gynecologic Oncology</i> , 2007, 106, 29-34.	0.6	168
14	Prospective study on stereotactic radiotherapy of limited-stage nonâ€”small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S128-S135.	0.4	78
15	Phase II study on stereotactic body radiotherapy of colorectal metastases. <i>Acta OncolÃ³gica</i> , 2006, 45, 823-830.	0.8	379
16	Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. <i>Radiotherapy and Oncology</i> , 2005, 76, 48-53.	0.3	323
17	Three-Dimensional Anal Endosonography May Improve Staging of Anal Cancer Compared With Two-Dimensional Endosonography. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 341-345.	0.7	40
18	No Rules without Exception: Long-Term Complete Remission Observed in a Study Using a LH-RH Agonist in Platinum-Refractory Ovarian Cancer. <i>Gynecologic Oncology</i> , 2002, 86, 297-301.	0.6	24

#	ARTICLE	IF	CITATIONS
19	Pulsed dose rate (PDR) brachytherapy as salvage treatment of locally advanced or recurrent gynecologic cancer. International Journal of Radiation Oncology Biology Physics, 1998, 42, 1041-1047.	0.4	29
20	Pulsed dose rate (PDR) brachytherapy of anal carcinoma. Radiotherapy and Oncology, 1996, 41, 131-134.	0.3	46
21	Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity. Cancer Chemotherapy and Pharmacology, 1992, 31, 46-52.	1.1	14
22	Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation. Cancer Chemotherapy and Pharmacology, 1990, 27, 194-198.	1.1	14
23	Effect of the Two Epipodophyllotoxins VP-16 and VM-26 on a Small Cell Carcinoma of the Lung Xenograft Grown in Nude Mice. , 1989, , 268-273.		0
24	Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines. Investigational New Drugs, 1989, 7, 307-15.	1.2	10
25	In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung. European Journal of Cancer & Clinical Oncology, 1989, 25, 1197-1201.	0.9	21
26	Can Human Small-Cell Lung Cancer Cell Lines be Applied for Optimizing Chemotherapy?. Cancer Treatment and Research, 1989, 45, 151-172.	0.2	1
27	The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells. Biochemical Pharmacology, 1988, 37, 3305-3310.	2.0	41
28	The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay. European Journal of Cancer & Clinical Oncology, 1988, 24, 247-253.	0.9	27
29	Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines. European Journal of Cancer & Clinical Oncology, 1987, 23, 177-186.	0.9	37
30	In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines. Cancer Chemotherapy and Pharmacology, 1987, 19, 315-8.	1.1	18
31	The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung. Cancer Chemotherapy and Pharmacology, 1987, 19, 16-20.	1.1	41
32	Endoscann Cell Sampling For Cytological Assessment of Endometrial Pathology. Acta Obstetrica Et Gynecologica Scandinavica, 1986, 65, 397-399.	1.3	6